Current Report Filing (8-k)
April 17 2019 - 11:16AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
April
17, 2019
|
Date of report (Date of earliest event reported)
|
Surmodics, Inc.
|
(Exact Name of Registrant as Specified in its Charter)
|
Minnesota
|
|
0-23837
|
|
41-1356149
|
(State of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
9924 West 74
th
Street
Eden Prairie, Minnesota
|
|
55344
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(952) 500-7000
|
(Registrant’s Telephone Number, Including Area Code)
|
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions
(see General Instruction A.2):
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
|
|
Emerging growth company
|
⃞
|
|
|
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
|
⃞
|
Item 8.01 Other Events.
On April 17, 2019, Surmodics, Inc. issued a press release providing an
update regarding the TRANSCEND clinical trial. A copy of a press
release announcing the foregoing is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
.
|
Exhibit
|
|
|
|
Number
|
|
Description
|
|
99.1
|
|
Press Release dated April 17, 2019.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
SURMODICS, INC.
|
|
|
|
|
|
|
|
|
Date:
|
April 17, 2019
|
|
/s/ Bryan K. Phillips
|
|
|
|
Bryan K. Phillips
|
|
|
|
Sr. Vice President, Legal and Human Resources,
|
|
|
|
General Counsel and Secretary
|
EXHIBIT INDEX
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Sep 2023 to Sep 2024